Guanfacine
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Guanfacine
- Generic name
- GUANFACINE
- Manufacturer
- Fosun Pharma USA, Inc
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 261c06ce-8708-d659-e063-6294a90ac381
- SPL ID
- 53ff602c-4688-bace-e063-6394a90a2ffd
- Version
- 2
- Effective date
- 2024-11-04
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:00:56
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 217638 | derived:openfda.application_number |
| application number | ANDA217638 | openfda.application_number | |
| brand name | Guanfacine | openfda.brand_name | |
| generic name | GUANFACINE | openfda.generic_name | |
| manufacturer name | Fosun Pharma USA, Inc | openfda.manufacturer_name | |
| ndc | package | 72266-258-55 | openfda.package_ndc |
| ndc | package | 72266-255-55 | openfda.package_ndc |
| ndc | package | 72266-256-55 | openfda.package_ndc |
| ndc | package | 72266-257-55 | openfda.package_ndc |
| ndc | product | 72266-258 | openfda.product_ndc |
| ndc | product | 72266-256 | openfda.product_ndc |
| ndc | product | 72266-257 | openfda.product_ndc |
| ndc | product | 72266-255 | openfda.product_ndc |
| ndc11 | package | 72266025655 | derived:openfda.package_ndc |
| ndc11 | package | 72266025555 | derived:openfda.package_ndc |
| ndc11 | package | 72266025755 | derived:openfda.package_ndc |
| ndc11 | package | 72266025855 | derived:openfda.package_ndc |
| rxcui | 862013 | openfda.rxcui | |
| rxcui | 862025 | openfda.rxcui | |
| rxcui | 862006 | openfda.rxcui | |
| rxcui | 862019 | openfda.rxcui | |
| spl id | 53ff602c-4688-bace-e063-6394a90a2ffd | id | |
| spl set id | 261c06ce-8708-d659-e063-6294a90ac381 | set_id | |
| unii | PML56A160O | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypotension, bradycardia, syncope: Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease or chronic renal failure. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Avoid concomitant use of drugs with additive effects unless clinically indicated. Advise patients to avoid becoming dehydrated or overheated ( 5.1 ). Sedation and somnolence: Occur commonly with guanfacine extended-release tablets. Consider the potential for additive sedative effects with CNS depressant drugs. Caution patients against operating heavy equipment or driving until they know how they respond to guanfacine extended-release tablets ( 5.2 ). Cardiac Conduction Abnormalities: May worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. Titrate slowly and monitor vital signs frequently ( 5.3 ). Rebound Hypertension: Abrupt discontinuation of guanfacine extended-release tablets can lead to clinically significant and persistent rebound hypertension. Subsequent hypertensive encephalopathy was also reported. To minimize the risk of rebound hypertension upon discontinuation, the total daily dose of guanfacine extended-release tablets should be tapered in decrements of no more than 1 mg every 3 to 7 days ( 5.4 ). 5.1 Hypotension, Bradycardia, and Syncope Treatment with guanfacine extended-release tablets can cause dose-dependent decreases in blood pressure and heart rate. Decreases were less pronounced over time of treatment. Orthostatic hypotension and syncope have been reported [see Adverse Reactions (6.1) ] . Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate guanfacine extended-release tablets slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated. Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. 5.2 Sedation and Somnolence Somnolence and sedation were commonly reported adverse reactions in clinical studies [see Adverse Reactions (6.1) ] . Before using guanfacine extended-release tablets with other centrally active depressants, consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with guanfacine extended-release tablets . Advise patients to avoid use with alcohol. 5.3 Cardiac Conduction Abnormalities The sympatholytic action of guanfacine extended-release tablets may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. Titrate guanfacine extended-release tablets slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs. 5.4 Rebound Hypertension In post marketing experience, abrupt discontinuation of guanfacine extended-release tablets has resulted in clinically significant and persistent rebound hypertension above baseline levels and increases in heart rate. Hypertensive encephalopathy has also been reported in association with rebound hypertension with both guanfacine extended-release tablets and immediate release guanfacine [see Adverse Reactions (6.2) ] . In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. Children commonly have gastrointestinal illnesses that lead to vomiting, and a resulting inability to take medications, so they may be especially at risk for rebound hypertension. To minimize the risk of rebound hypertension upon discontinuation, the total daily dose of guanfacine extended-release tablets should be tapered in decrements of no more than 1 mg every 3 to 7 days [see Dosage and Administration (2.5) ] . Blood pressure and heart rate should be monitored when reducing the dose or discontinuing guanfacine extended-release tablets. If abrupt discontinuation occurs (especially with concomitant stimulant use), patients should be closely followed for rebound hypertension. 5.5 Risk of Allergic Reactions Due to Tartrazine This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table width="100%"><caption>Table 6: Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 4</caption><colgroup><col align="left" valign="top" width="40%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/><col align="center" valign="top" width="15%"/></colgroup><thead><tr styleCode="Botrule First"><th align="left" styleCode="Lrule Rrule"/><th align="center" styleCode="Rrule"/><th align="center" colspan="3" styleCode="Rrule">Guanfacine Extended-Release Tablets</th></tr><tr><th align="center" styleCode="Lrule Rrule">Adverse Reaction Term</th><th align="center" styleCode="Rrule">Placebo (N=112) </th><th align="center" styleCode="Rrule">AM (N=107) </th><th align="center" styleCode="Rrule">PM (N=114) </th><th align="center" styleCode="Rrule">All Doses of Guanfacine Extend-Release Tablets (N=221)</th></tr></thead><tfoot><tr><td align="left" colspan="5">a: The somnolence term includes somnolence, sedation, and hypersomnia. b: The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness c: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased). d: The enuresis term includes enuresis, nocturia, and urinary incontinence. </td></tr></tfoot><tbody><tr styleCode="Botrule First"><td align="left" styleCode="Lrule Rrule">Somnolence <sup>a</sup></td><td align="center" styleCode="Rrule">15%</td><td align="center" styleCode="Rrule">57%</td><td align="center" styleCode="Rrule">54%</td><td align="center" styleCode="Rrule">56%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Abdominal Pain <sup>b</sup></td><td align="center" styleCode="Rrule">7%</td><td align="center" styleCode="Rrule">8%</td><td align="center" styleCode="Rrule">19%</td><td align="center" styleCode="Rrule">14%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Fatigue</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">10%</td><td align="center" styleCode="Rrule">11%</td><td align="center" styleCode="Rrule">11%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Irritability</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">7%</td><td align="center" styleCode="Rrule">7%</td><td align="center" styleCode="Rrule">7%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Nausea</td><td align="center" styleCode="Rrule">1%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">5%</td><td align="center" styleCode="Rrule">5%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Dizziness</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">5%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Vomiting</td><td align="center" styleCode="Rrule">2%</td><td align="center" styleCode="Rrule">7%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">5%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Hypotension <sup>c</sup></td><td align="center" styleCode="Rrule">0%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">5%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Decreased Appetite</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">4%</td></tr><tr><td align="left" styleCode="Lrule Rrule">Enuresis <sup>d</sup></td><td align="center" styleCode="Rrule">1%</td><td align="center" styleCode="Rrule">2%</td><td align="center" styleCode="Rrule">5%</td><td align="center" styleCode="Rrule">4%</td></tr></tbody></table>
adverse reactions table
<table width="100%"><caption>Table 7: Adverse Reactions Leading to Discontinuation (≥2% for all doses of guanfacine extended-release tablets and >rate than in placebo) in Monotherapy Flexible Dose Study 4</caption><colgroup><col align="left" valign="top" width="22%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="9%"/><col align="center" valign="top" width="12%"/><col align="center" valign="top" width="12%"/></colgroup><thead><tr styleCode="Botrule First"><th align="left" styleCode="Lrule Rrule"/><th align="center" colspan="2" styleCode="Rrule"/><th align="center" colspan="6" styleCode="Rrule">Guanfacine Extended-Release Tablets</th></tr><tr styleCode="Botrule"><th align="center" styleCode="Lrule Rrule">Adverse Reaction Term</th><th align="center" colspan="2" styleCode="Rrule">Placebo (N=112) </th><th align="center" colspan="2" styleCode="Rrule">AM (N=107) </th><th align="center" colspan="2" styleCode="Rrule">PM (N=114) </th><th align="center" colspan="2" styleCode="Rrule">All Doses of Guanfacine Extended-Release Tablets (N=221)</th></tr><tr><th align="left" styleCode="Lrule Rrule"/><th align="center">n</th><th align="center" styleCode="Rrule">(%)</th><th align="center">n</th><th align="center" styleCode="Rrule">(%)</th><th align="center">n</th><th align="center" styleCode="Rrule">(%)</th><th align="center">n</th><th align="center" styleCode="Rrule">(%)</th></tr></thead><tfoot><tr><td align="left" colspan="9">Adverse reactions leading to discontinuation in ≥2% in any dose group but did not meet this criteria in all doses combined: fatigue a: The somnolence term includes somnolence, sedation, and hypersomnia. </td></tr></tfoot><tbody><tr styleCode="Botrule First"><td align="left" styleCode="Lrule Rrule">Total patients</td><td align="center">0</td><td align="center" styleCode="Rrule">(0%)</td><td align="center">8</td><td align="center" styleCode="Rrule">(7%)</td><td align="center">7</td><td align="center" styleCode="Rrule">(6%)</td><td align="center">15</td><td align="center" styleCode="Rrule">(7%)</td></tr><tr><td align="left" styleCode="Lrule Rrule">Somnolence <sup>a</sup></td><td align="center">0</td><td align="center" styleCode="Rrule">(0%)</td><td align="center">4</td><td align="center" styleCode="Rrule">(4%)</td><td align="center">3</td><td align="center" styleCode="Rrule">(3%)</td><td align="center">7</td><td align="center" styleCode="Rrule">(3%)</td></tr></tbody></table>
adverse reactions table
<table width="100%"><caption>Table 8: Other Common Adverse Reactions (≥2% for all doses of guanfacine extended-release tablets and >rate than in placebo) in the Monotherapy Flexible Dose Study 4</caption><colgroup><col align="left" valign="top" width="20%"/><col align="center" valign="top" width="16%"/><col align="center" valign="top" width="17%"/><col align="center" valign="top" width="17%"/><col align="center" valign="top" width="30%"/></colgroup><thead><tr styleCode="Botrule First"><th align="left" styleCode="Lrule Rrule"/><th align="center" styleCode="Rrule"/><th align="center" colspan="3" styleCode="Rrule">Guanfacine Extended-Release Tablets</th></tr><tr><th align="center" styleCode="Lrule Rrule">Adverse Reaction Term</th><th align="center" styleCode="Rrule">Placebo (N=112) </th><th align="center" styleCode="Rrule">AM (N=107) </th><th align="center" styleCode="Rrule">PM (N=114) </th><th align="center" styleCode="Rrule">All Doses of Guanfacine Extended-Release Tablets (N=221)</th></tr></thead><tfoot><tr><td align="left" colspan="5">Adverse reactions ≥2% for all doses of guanfacine extended-release tablets and >rate in placebo in any dose group but did not meet this criteria in all doses combined: affect lability (affect lability, mood swings), increased weight, syncope/loss of consciousness (loss of consciousness, presyncope, syncope), dyspepsia, tachycardia (tachycardia, sinus tachycardia), and bradycardia (bradycardia, sinus bradycardia). a: The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder. </td></tr></tfoot><tbody><tr styleCode="Botrule First"><td align="left" styleCode="Lrule Rrule">Headache</td><td align="center" styleCode="Rrule">11%</td><td align="center" styleCode="Rrule">18%</td><td align="center" styleCode="Rrule">16%</td><td align="center" styleCode="Rrule">17%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Insomnia <sup>a</sup></td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">8%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">7%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Diarrhea</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">5%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Lethargy</td><td align="center" styleCode="Rrule">0%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">3%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Constipation</td><td align="center" styleCode="Rrule">2%</td><td align="center" styleCode="Rrule">2%</td><td align="center" styleCode="Rrule">4%</td><td align="center" styleCode="Rrule">3%</td></tr><tr><td align="left" styleCode="Lrule Rrule">Dry Mouth</td><td align="center" styleCode="Rrule">1%</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">3%</td></tr></tbody></table>
adverse reactions table
<table width="100%"><caption>Table 9: Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 5</caption><colgroup><col align="left" valign="top" width="33%"/><col align="center" valign="top" width="33%"/><col align="center" valign="top" width="34%"/></colgroup><thead><tr styleCode="First Last"><th align="center" styleCode="Lrule Rrule">Adverse Reaction Term</th><th align="center" styleCode="Rrule">Placebo (N=155) </th><th align="center" styleCode="Rrule">All Doses of Guanfacine Extended-Release Tablets (N=157)</th></tr></thead><tfoot><tr><td align="left" colspan="3">a: The somnolence term includes somnolence, sedation, and hypersomnia. b: The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder. c: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased). d: The bradycardia term includes bradycardia and sinus bradycardia. </td></tr></tfoot><tbody><tr styleCode="Botrule First"><td align="left" styleCode="Lrule Rrule">Somnolence <sup>a</sup></td><td align="center" styleCode="Rrule">23%</td><td align="center" styleCode="Rrule">54%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Insomnia <sup>b</sup></td><td align="center" styleCode="Rrule">6%</td><td align="center" styleCode="Rrule">13%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Hypotension <sup>c</sup></td><td align="center" styleCode="Rrule">3%</td><td align="center" styleCode="Rrule">9%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Dry Mouth</td><td align="center" styleCode="Rrule">0%</td><td align="center" styleCode="Rrule">8%</td></tr><tr styleCode="Botrule"><td align="left" styleCode="Lrule Rrule">Postural Dizziness</td><td align="center" styleCode="Rrule">2%</td><td align="center" styleCode="Rrule">5%</td></tr><tr><td align="left" styleCode="Lrule Rrule">Bradycardia <sup>d</sup></td><td align="center" styleCode="Rrule">0%</td><td align="center" styleCode="Rrule">5%</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.